Merck Animal Health to Showcase Latest Innovations in Veterinary Medicine at WSAVA 2026
14 October 2026, Rahway: Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will host scientific symposia showcasing the latest clinical advancements in canine allergic dermatitis, parasite protection, and infectious disease prevention protocols at the 2026 World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland.
“Sharing our latest innovations at WSAVA reflects how MSD Animal Health continues to help drive transformative veterinary medicine for companion animals and those that care for them. We are focused on advancing companion animal health through treatment and prevention in parasite control and well-being,” said Delair Bolis, associate vice president, Global Companion Animals, MSD Animal Health. “We are proud to lead the industry with solutions that help make a meaningful difference for pets and their caregivers worldwide.”
At this year’s Congress, attendees are invited to visit the MSD Animal Health booth (#04) to explore the latest breakthroughs shaping veterinary medicine, including the launch of NOBIVAC® NXT Feline vaccines, the innovation of NUMELVI®, extended parasite protection with BRAVECTO® Injectable, and the 30-year milestone of the AFYA Program’s global rabies elimination mission.
Key Symposia at WSAVA:
Breaking the Itch Cycle: Diagnosis, Treatment, and Prevention of Allergic Dermatitis
Tuesday, October 13, 2026: 13:15-14:15
Parallel Hall 5
Presenters: Linda Horspool, BVMS, PhD, DECVPT, MRCVS; Patrick Hensel, DVM, DACVD, DECVD; Galia Sheinberg, DVM, ESP, DLACVD; Dawid Janczak, DVM, PhD
This comprehensive veterinary symposium delivers an end-to-end clinical framework for tackling allergic dermatitis, guiding practitioners from initial diagnosis through long-term disease management. The program begins with a stepwise diagnostic approach to systematically rule out differentials and confirm underlying allergic conditions, followed by evidence-based multimodal strategies, including targeted anti-inflammatory therapy, rapid pruritus control, and skin barrier restoration, tailored to individual patient needs. Rounding out the sessions, the symposium emphasizes the critical role of continuous, year-round flea control in preventing and mitigating flare-ups, equipping veterinary professionals with practical, integrated solutions to optimize patient comfort and dermatologic outcomes.
Retrovirus Reality Check: Cracking the Code of FeLV & FIV
Wednesday, October 14, 2026: 12:45-13:45
Parallel Hall 4
Presenters: Melissa Bourgeois, DVM, PhD, DACVM; Petra Cerna, PhD, DACVIM, Dipl. ECVIM-CA, DABVP, MANZCVS
This clinical session delivers a comprehensive overview of feline retrovirus infections, equipping veterinary teams with actionable strategies for the diagnosis, clinical evaluation, and long-term management of feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Attendees will explore primary and confirmatory testing methodologies alongside practical approaches to managing clinical signs and associated comorbidities in infected cats. Additionally, the lecture introduces NOBIVAC NXT Feline, detailing the science behind its cutting-edge RNA particle technology and demonstrating how this next-generation vaccine can proactively advance feline preventive care and elevate standard protocol outcomes in clinical practice.
Also Read: FMC Wins UK Approval for New Cyantraniliprole Formulations in Potatoes and Carrots
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com
